Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artemether-lumefantrine and dihydroartemisinin-piperaquine for uncomplicated falciparum malaria in young children in Togo
ACTRN12623000344695Phase 4Completed
- Sponsor
- Ministry of Health of Togo
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of artemether + lumefantrine and dihydroartemisinin + piperaquine in malaria and Falciparum malaria (PF) (2 arms), sponsored by Ministry of Health of Togo. Primary endpoint: Proportion of treatment failures. Started Sep 2021; status: completed.
02
Drugs
artemether + lumefantrinedihydroartemisinin + piperaquine
03
Conditions
malariaFalciparum malaria (PF)
Beyond the preview
Go deeper on ACTRN12623000344695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000344695.